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The relationship between tissue levels of flavone acetic acid (NSC 37512)
and site dependent anti-tumour activity in murine colon tumours
M.C. Bibby, R.M. Phillips & J.A. Double
Clinical Oncology Unit, University ofBradford, Bradford BD7 JDP, UK
Summary Flavone acetic acid (FAA) is extremely active against subcutaneous transplantable tumours in
mice, but disappointingly there has been no demonstrable clinical activity. Previous studies have shown that
lung tumour deposits are less responsive than the same cells implanted subcutaneously. The aim of this study
is to examine the tissue disposition of FAA in an attempt to explain this site-dependent activity. The data
show clearly that FAA clearance curves are influenced by the presence of MAC 15A tumours growing either
subcutaneously or systemically. The decreased clearance of FAA from MAC 15A tumour bearing animals
does not however explain the resistance of lung deposits. Neither can this be explained by differences in
metabolism in these different sites. Cytotoxic metabolites have not been detected either in vitro or in vivo and
their role in the mechansim of action of FAA is questionable.
Flavone acetic acid (2-phenyl-8-[carboxymethyl]-benzopyran-
4-one NSC 347512) (FAA) is a compound that is capable of
inducing significant responses in several murine solid
tumours (Corbett et al., 1986; Plowman et al., 1986; Bibby et
al., 1987b) although no objective responses have been
observed in clinical trials (Kerr et al., 1987, 1989). The
reasons for these discrepancies are unknown although differ-
ences in the mechanism of action of FAA between mouse
and man may be significant. In murine tumour models, the
action of FAA is characterised by the rapid shutdown of
tumour vasculature, the appearance of haemorrhagic necrosis
within 4 h of drug administration, and activity against
advanced solid tumours that are normally resistant to con-
ventional cytotoxic agents (Bibby et al., 1989a; Zwi et al.,
1989). One further characteristic of FAA induced responses
is that activity is dependent upon the site of tumour implan-
tation (Bibby et al., 1989b; Giavazzi et al., 1988). Recent
studies in this laboratory have demonstrated that murine
colon tumours (MAC) grown subcutaneously respond to
FAA (90% tumour inhibiton) whereas the same cells grown
systemically (as small spheroid-like nodules in the lung) or
intraperitoneally (as ascites) do not respond (Bibby et al.,
1989b). The reasons for these site dependent responses are
unknown although differences in drug distribution between
tumours with different histological characteristics and vas-
cular supply may be a highly significant factor. The aim of
this study therefore is to assess whether or not differences in
FAA bioavailability can explain the spectrum of anti-tumour
activity observed in the murine colon tumour model, MAC
15A. In addition, preliminary studies incorporating S-9 liver
fractions or plasma from responding tumour bearing mice
were conducted in vitro to further study the possibility of a
cytotoxic metabolite being responsible for the anti-tumour
activity of FAA as suggested by Chabot et al. (1989a).
Materials and methods
Animals
Pure strain NMRI mice (6-8 weeks of age) were used from
our inbred colony. They received CRM diet (Labsure, Croy-
don, England) and water ad libitum.
Test compounds
Clinically formulated FAA was a gift from Lipha (Lyon,
France). It was dissolved in physiological saline at an appro-
priate concentration for a desired dose to be administered in
0.1 ml per 10 g body weight.
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Tumour system
The development of several adenocarcinomas of the large
bowel in NMRI mice from primary tumours induced by
prolonged administration of 1-2-dimethylhydrazine has been
described previously (Double et al., 1975, Bibby et al.,
1987a). MAC 15A ascitic tumour cells (1 x 106) were im-
planted via the intravenous (iv) and subcutaneous (sc) route.
Tumour bearing animals were treated at day 12 with a dose
of 200 mg kg-' FAA in line with protocols described by
Bibby et al. (1989b).
Measurement ofdrug concentrations in plasma and tissues
Sample collection: Blood samples from three mice at each
time point were taken by cardiac puncture under ether anaes-
thesia, collected into heparinised tubes, centrifuged at 1000g
and 4°C for 10 min and the separated plasma was stored at
-20°C until analysis. The rapidly dissected tissues and
tumours were immediately frozen in liquid nitrogen and
stored at -20°C. Samples were stored for less than 1 week
during which time no degradation of FAA was observed.
Each pharmacokinetic profile was repeated twice using three
mice per time point. For the first run, 12 time points were
studied ranging from 1 min to 18 h after the administration
of FAA (200 mgkg-' ip). In repeat experiments, four time
points (15 min, 1, 8 and 12 h) were studied. In the sub-
cutaneous tumour study mean MAC 15A sc tumour weight
was 0.55 g ± 0.21 (range 0.19 ± 0.92 g). In the case of MAC
15A iv tumours, mice were treated approximately 14 days
after the iv inoculation of 1 x 106 cells at which time there
were extensive tumour deposits in the lung. Measurement of
FAA concentration in the lungs of MAC 15A iv tumour
bearing mice was taken to represent tumour drug concentra-
tions as dissection of normal from tumour tissue is not
possible.
Sample extraction and chromatography
FAA was extracted from plasma and tissue homogenates
(10% w/v in acetate buffer pH 4.0) using C18 Bond Elut
cartridges (Analytichem International). Cartridges were acti-
vated by passing ethanol (1 ml) through, under vacuum (Vac
Elut system - Analytichem International) and washed with
acetate buffer (1 ml). Plasma samples (50jll plasma, 50ILI
internal standard [100pgml-' p-dimethylaminobenzaldehyde]
and 100p1 acetate buffer) and tissue samples (100 IA homo-
genate plus 100 lI internal standard, 10 gml-') were applied
to each cartridge. Following a further wash (1 ml acetate
buffer), FAA was eluted in 500pl ethanol. Extraction
efficiency of FAA was greater than 90%.
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FAA was measured by reverse phase HPLC, details of
which have been published elsewhere (Kerr et al., 1985;
Double et al., 1986). Standard curves were prepared by the
addition of FAA to buffered control mouse plasma (pH 4.0)
and plotting the ratio of peak area of FAA to internal
standard against drug concentration. The assay was sensitive
to drug concentrations down to 10ngml-'.
Pharmacokinetic parameter determination
All pharmacokinetic parameters were calculated using stan-
dard formulae (Gibaldi, 1984). The terminal half life (t1) was
calculated by least square linear regression analysis of the
terminal log linear phase of the curve and the elimination
constant (KeI) determined from the relationship Kei = 0.693/
t4. The area under the curve (AUC) from time 0 to the last
measured time point (tj) was calculated using the trapezoid
rule. The remaining area from t, to co was calculated using the
equation Cz/Kel where C, equals the concentration at t,. Total
body clearance (CIT) was calculated as dose/AUC. Volume of
distribution was calculated as dose/C0 where C0 is the con-
centration at time 0.
Results
FAA was administered to tumour bearing and non-tumour
bearing mice at 200 mg kg-' ip, and the resulting plasma and
tissue concentrations of FAA at various times thereafter are
presented in Figures 1 and 2. In all cases the elimination of
FAA was biphasic. The presence of MAC 15A tumours
grown iv or sc has a significant effect upon the pharmaco-
kinetic behaviour of FAA compared to non-tumour bearing
mice. In both MAC 15A iv and sc tumour bearing mice the
total body clearance of FAA is reduced in all tissues com-
pared with non tumour bearing mice resulting in significant
E
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Plasma protein binding
Protein binding of FAA in plasma of non-tumour bearing
and MAC 15A bearing mice was examined at 15 min and 8 h
after FAA administration. Plasma samples were divided into
two aliquots, one of which was extracted and analysed as
described above the other being added to a Centrifreem
micropartition system (Amicon). Following centrifugation at
200g for 20 min the ultrafiltrate was collected and FAA was
extracted and analysed as described above. I) 0)
Preparation ofS-9 liverfractions and chemosensitivity studies
in vitro
S-9 microsomes were prepared from normal and phenobar-
bitone pre-treated mice (60 mgkg' ip for 4 days) by the
methods described by Chabot et al. (1989a). Mice were
sacrificed by cervical dislocation and livers were aseptically
excised and gently homogenised in four times their weight of
cold RPMI 1640 tissue culture medium (pH 7.4) using a
motor driven teflon/glass homogeniser and centrifuged at
9,000g for 20 min at 4°C. One ml of this supernatent was
added to a sterile universal tube containing 3 ml of MAC
15A cells in suspension. To this 0.5 ml FAA (1-5 mg ml-')
and 0.5 ml of co-factors (glucose-6-phosphate, 33 mg ml-'
NADP, 4 mgml-'; MgCI2.6H20, 6.6 mgml-' and glucose-6-
phosphate dehydrogenase, 1.66 units) were added and incub-
ated at 37°C for 1 h. Following drug exposure, cytotoxic
effects were assessed using a clonogenic assay, the details of
which have been published elsewhere (Phillips et al., 1988).
All assays were performed in triplicate and cells in the expon-
tial phase of growth were used throughout. Controls contain-
ing S-9 preparations and co-factors were used as well as a
positive control assay using cyclophosphamide (0.5 to 2 mg
ml-' for 1 h).
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Influence ofFAA containing mouse plamsa on cytotoxicity in
vitro
Blood samples from normal mice and mice bearing sub-
cutaneous MAC 15A tumours were collected by cardiac
puncture I h and 4 h after the ip administration of a thera-
peutic dose of FAA (200 mg kg-'). Blood was immediately
centrifuged and plasma samples (1 ml) added directly to a
pellet of MAC 15A cells and incubated at 3TC for 1 h.
Following exposure to plasma samples the cells were washed
and chemosensitivity was assessed as described previously.
For control cultures FAA, at peak plasma drug concentra-
tions (0.6 mg ml-') was added to fresh mouse plasma.
Plasma
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Figure 1 Means concentration of FAA± I s.d. in plasma and
tissues of non tumour bearing NMRI mice (A) and mice im-
planted with MAC 15A tumour cells by the iv (0) and sc (A)
route 12 days earlier. FAA was given at a single ip dose of
200 mg kg-'. Values presented are the means of three mice per
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Figure 2 Mean concentration of FAA± I s.d. in plasma (A) and
MAC 15A tumours (A) growing subcutaneoulsy in NMRI mice
following a single ip dose of 200mg kg-'. Values presented are
the means of three mice per time point.
increases in AUC>. values (Table I). The increase in plasma
AUC>0 values in MAC 15A iv and sc tumour bearing mice
relative to non-tumour bearing mice (AUCTB/AUCNTB = 2.4
and 2.6 respectively, TB = tumour bearing, NTB = non
tumour bearing) is not accompanied by an increase in peak
plasma drug concentrations (PeakTB/PeakNTB = 0.91 and 1.12
respectively, Table II).
The relationship between peak concentrations or AUC
values of FAA in tumour samples and anti-tumour activity is
presented in Table III. For the purposes ofcomparison, three
additional MAC tumours (MAC 15Aip, MAC 16 and 26)
have been included, details of pharmacokinetic exposures at
the tumour site have been published elsewhere (Bibby et al.,
1987b; Bibby et al., 1988; Bibby et al., 1989a). There is a
poor correlation between pharmacokinetic parameters at the
tumour site and the final outcome of chemotherapy in vivo.
In both the resistant MAC 15A ip and iv tumour lines AUC
and peak levels of FAA are higher than these achieved in the
very responsive MAC 16 tumour (Table III). Plasma protein
binding of FAA is presented in Table IV. There are no
significant differences in plasma protein binding between
non-tumour and MAC 15A iv and sc tumour bearing mice
with values ranging from 68.7% to 85.6%.
The cytotoxic activity of FAA in vitro was not enhanced
by the inclusion of S-9 or phenobarbitone induced S-9 liver
fractions in the incubation mixture (Figure 3). The positive
control compound, cyclophosphamide is activated by the S-9
liver preparation. No cell kill was observed in MAC 15A
cells exposed to plasma from responding tumour bearing
mice.
Discussion
Two main conclusions can be drawn from the results present-
ed in this study; first, the presence of MAC 15A tumours has
a significant influence upon the pharmacokinetic behaviour
of FAA and second, that the site-dependent response of
MAC 15A tumours cannot be explained on the basis of poor
drug bioavailability.
The reasons for altered pharmacokinetics in MAC 15A
tumour bearing mice relative to non tumour bearing mice are
unknown although it is clearly not due to differences in
Table I Plasma and tissue distribution of FAA following the ip administration of FAA (200 mgkg-')
c.a T.. T, K"i Vd CIT AUCO0b
(llgg-') (h) (h) (h-') (Lkg-') (L h.-) (SAgh.g-)
Non tumour bearing mice
Plasma 511 0.25 3.5 0.198 0.357 0.138 1443
586 0.25 3.1 0.224 0.307 0.097 2058
Kidney 136 0.16 2.7 0.256 1.25 0.401 499
243 0.25 2.8 0.247 0.77 0.203 984
Liver 239 0.25 2.7 0.256 0.661 0.277 720
383 0.25 3.4 0.203 0.467 0.137 1455
Lung 113 0.25 1.3 0.529 1.48 0.888 225
167 0.25 1.5 0.462 1.05 0.358 558
MAC 15A iv
Plasma 520 0.25 8.6 0.080 0.37 0.056 3526
474 0.25 8.5 0.081 0.39 0.041 4878
Kidney 183 0.25 10.5 0.066 1.01 0.144 1384
157 0.25 8.9 0.077 1.18 0.118 1697
Liver 222 0.166 9.9 0.070 0.81 0.112 1770
290 0.25 7.5 0.093 0.65 0.061 3237
Lungc 137 0.083 6.9 0.101 1.38 0.271 740
119 0.25 6.4 0.107 1.54 0.287 696
MAC ISA sc
Plasma 610 0.25 9.2 0.075 0.31 0.037 5356
536 0.25 8.7 0.079 0.35 0.052 3859
Kidney 155 0.25 12.6 0.055 1.14 0.112 1789
239 0.25 7.3 0.094 0.82 0.098 2036
Liver 375 0.08 5.8 0.119 0.51 0.072 2776
361 0.25 5.4 0.129 0.53 0.078 2573
Lung 169 0.25 6.9 0.101 1.11 0.198 1009
192 0.25 6.9 0.101 1.01 0.162 1236
Tumour 136 1 12.6 0.055 0.95 0.114 1784
151 1 6.9 0.101 0.83 0.159 1251
aUnits for plasma levels are jigml1; bUnits for plasma AUC values are jig h.ml '; CN.B. Lung tissues
contain extensive tumour deposits at the time of chemotherapy. For each tissue results from two
independent experiments are presented. Ke, = Elimination constant; T, = Terminal halflife; Cm. = Peak
concentration+s.d.; Tmax =Time of peak concentration; CIT = Total body clearance; Vd = Apparent
volume ofdistribution; AUC>< = Area under the curve.
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Table II Summary ofpeakplasmaandplasma AUC valuesin tumour
bearing and non tumour bearing mice
Peaka plasma
values
(fig ml- )
Ratio
peakT b
peakNTB
Plasmaa
AUC(O-)
(figh.mt-')
100 -
Ratio
AUCTB
AUCNTB
MAC 1SA iv 497 0.91 4202 2.4
MAC 15A sc 573 1.04 4608 2.6
Non tumour 549 1.00 1751 1.0
bearing
aMean values for two experiments with three mice per point in each
experiment. "TB = Tumour bearing; NTB = Non tumour bearing.
Table III Relationship between tumour pharmacokinetic parameters
and anti-tumour activity
Dose and % Twnourc
route Peak' conc AUC(o_j) inhibition
(mgkg-') (fsgg ) (llgh.g- ) in vivo
MAC 15A ivd 200 ip 128 718 0
MAC 15A sc 200 ip 144 1517 90
MAC 15A ipe 200 ip 3100 3210 0
MAC 16' 200 ip 41 500 100
MAC 269 200 ip 130 1260 82
aUnits for peritoneal washings are gLgml-'; bUnits for peritoneal
washings arefig h.ml-'; cTumour inhibition assessed by: (1) MAC 15A
ip and iv: survival times; (2) MAC 1SA sc: tumour weight; (3) MAC 16
and 26: growth delay; dPeak and AUC values for FAA represent those
achieved in lung tissues which contain extensive tumourdeposits at the
time ofchemotherapy; eBibbyetal., 1987b; fBibby etal., 1988;"Bibbyet
al., 1989a; All drug values presented are the mean of two experiments
with three mice per point in each experiment.
Table IV Plasma protein binding of FAA
Dose Time % Bindinga
(mgkg-') (min) Expt.A. Expt.B.
Non tumour 200 ip 15 75.8±6.1 78.4±4.8
bearing 480 84.1 ± 5.9 81.7±8.2
MAC ISA sc 200 ip 15 70.8±7.1 68.7±7.5
480 81.4±3.6 85.6±9.1
MAC ISA iv 200 ip 15 74.2± 5.4 76.6±8.1
480 78.6±4.9 85.2±4.7
'Values presented are the means±standard deviations from two
independent experiments (three mice per point in each experiment).
plasma protein binding (Table IV). It also seems unlikely that
this phenomenon is a direct result of the dose dependent,
non-linear characteristic of FAA pharmacokinetics (Damia et
al., 1988; Chabot et al., 1989b) as the increase in plasma
AUC-,0 in tumour bearing mice is not accompanied by an
increase in peak concentrations (Table II). Whether or not
saturation of tubular secretion is involved in this case re-
mains an open question. A much more likely explanation is a
combination of host factors such as depression of metabolic
capacity, impaired kidney function etc caused by an aggres-
sively growing tumour (Donelli et al., 1984).
Whatever the mechanism, the relevance of these changes to
anti-tumour activity appear to be limited, as increases in
plasma and tissue AUC&, values for FAA occur in both the
resistant MAC 15A iv and the sensitive MAC 15A sc models
(Table I). In addition, such significant increases in plasma
and tissue AUC values for FAA were not observed in MAC
26 and MAC 16 tumours, both of which are sensitive to
FAA (Cummings et al., 1989; Bibby et al., 1988). In terms of
tolerance however, these observations may be relevant partic-
ularly as Zaharko et al. (1986) have shown that increased
lethality results from too long an exposure to therapeutically
effective concentrations of FAA. Further detailed studies on
the relationship between AUC and tolerance in normal and
tumour-bearing mice are under way.
The relationship between tumour levels (both peak concen-
trations and AUC<,>, values) and anti-tumour activity in vivo
(Table III) clearly demonstrates that the lack of activity
cn
2 3
FAA (mg ml'1)
4 5
Figure 3 In vitro chemosensitivity of MAC 15A cells following a
I h exposure to FAA and cyclophosphamide with and without
addition of mouse liver S-9 fractions. Cyclosphosphamide (CPA)
(*); FAA (A); CPA + S-9 (O); FAA + S-9 (A); FAA + pheno-
barbitone induced S-9 (0). All points represent the means of
three independent experiments±s.d.
against MAC 15A ip and iv tumours is unlikely to be the
result of limited drug penetration. Concentrations of FAA in
the lungs of unresponsive MAC 15A iv tumour bearing mice
(AUC>,D, = 718 fig h.g-') for example are similar to those
achieved in the very responsive MAC 16 tumour (500tig
h.g-'). Furthermore, additional studies including Phase I
clinical trials have shown that plasma concentrations of FAA
associated with activity in mice are achievable in humans
which strongly suggests that poor penetration of FAA into
human tumours is unlikely to explain the lack of activity
observed in clinical studies (Maughan et al., 1989; Kerr et al.,
1987).
Two metabolites of FAA were detected in vivo. The first
metabolite eluted was present at low levels (7% ofcirculating
FAA) in plasma samples but was barely detectable in other
tissues. Similar findings have been reported in NMRI mice
(Cummings et al., 1989) and Balb/c mice (Damia et al.,
1988). The second metabolite could only be detected in liver
samples. Attempts to identify cytotoxic metabolites in vivo or
to activate FAA to a cytotoxic species in vitro failed to
substantiate the results presented by Chabot et al. (1989a). In
this and previous studies (Damia et al., 1988), no metabolites
arising from the inclusion of S-9 liver fractions in the incuba-
tion 'mix' in vitro were detected by HPLC. Furthermore, as
no metabolites could be detected in tumour tissues, their role
in the anti-tumour activity of FAA remains questionable.
In conclusion, the results of this study have demonstrated
that the site dependent activity of FAA cannot be fully
explained on the basis of differences in drug and/or meta-
bolite bioavailability or on altered pharmacokinetic profiles
caused by the presence of large tumour loads. The reasons
for the site dependent activity of FAA remain unclear
although it is likely that the activity of FAA against sc
tumours relies in part on the specific vascular feature of
tumours at this site.
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